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Abstract
Background
It’s currently well known that smoking and increasing age constitute the most important risk
factors for chronic obstructive pulmonary disease (COPD). However, little is known about
COPD among nonsmokers. The present study aimed to investigate prevalence, risk factors
and the profiles of COPD among nonsmokers based on the Tunisian Burden of Obstructive
Lung Disease (BOLD) study.
Methods
807 adults aged 40 years+ were randomly selected from the general population. We col-
lected information about history of respiratory disease, risk factors for COPD and quality of
life. Post-bronchodilator spirometry was performed for assessment of COPD. COPD diag-
nostic was based on the post-bronchodilator FEV1/FVC ratio, according to the Global Initia-
tive for Obstructive Lung Disease (GOLD) guidelines. The lower limit of normal (LLN) was
determined as an alternative threshold for the FEV1/FVC ratio.
Results and Conclusions
Among 485 nonsmokers, 4.7%met the criteria for GOLD grade I and higher COPD. These
proportions were similar even when the LLN was used as a threshold. None of the non-
smokers with COPD reported a previous doctor diagnosis of COPD compared to 7.1% of
smokers. Nonsmokers accounted for 45.1% of the subjects fulfilling the GOLD spirometric
criteria of COPD. Nonsmokers were predominately men and reported more asthma prob-
lems than obstructed smokers. Among nonsmokers significantly more symptoms and
higher co-morbidity were found among those with COPD. Increasing age, male gender,
occupational exposure, lower body mass index and a previous diagnosis of asthma are
associated with increased risk for COPD in nonsmokers. This study confirms previous evi-
dence that nonsmokers comprise a substantial proportion of individuals with COPD.
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Nonsmokers with COPD have a specific profile and should, thus, receive far greater atten-
tion to prevent and treat chronic airway obstruction.
Introduction
Chronic obstructive pulmonary disease (COPD) represents a major public health problem and
one of the leading causes of morbidity and mortality worldwide. The population prevalence of
COPD is growing in developing countries and especially in North Africa [1–2]. Among the
major causes of COPD, the role of tobacco smoking is well recognized and accordingly, recent
studies of COPD have been largely focused on the smoking rather than the non-smoking popu-
lation [3]. However, there is current evidence that never smokers can also develop chronic air-
flow obstruction and might thus comprise a substantial proportion of this disorder [4].
According to a recent review of the American Thoracic Society (ATS), a substantial proportion
of COPD cases are not associated with smoking, especially among women and residents of
developing countries [5]. Several factors have been implicated such as occupational exposure
and respiratory problems in childhood as causes of airways obstruction. Outdoor air pollution,
second hand smoke, biomass smoke and chronic asthma are leading causes of lung function
decrement and irreversible airway obstruction among nonsmokers. This problem is more prev-
alent in developing countries compared with the developed ones [5,6,7]. However, our under-
standing of these risk factors for the development of chronic non-reversible airway obstruction
in nonsmokers is still incomplete and only a few studies have described this population in
greater details [8–9]. Therefore, insights into the epidemiology of COPD in nonsmokers may
be of interest.
To investigate the prevalence and risk factors of COPD among nonsmokers, we used the
data of the population-based Tunisian Burden of Obstructive Lung Disease (BOLD) study. We
reported the prevalence of COPD in nonsmokers and described the clinical presentation and
the severity of the disease and particularly associated risk factors.
Materials and Methods
This study was approved by the ethics committee of the Medical School of Sousse and written
informed consent was obtained from all the participants.
Study population
We followed the BOLD protocol as it has been described elsewhere [10,11,12]. The survey was
conducted on a gender-stratified representative random sample of civilian, non-institutional-
ized residents selected from the general population living in the urban area of Sousse (Tunisia).
Two quartiers with clear administrative boundaries were selected for convenience (Erriadh
and Jawhara) and districts were sampled at random from each of the two selected quartiers (9
districts from Erriadh and 8 districts from Jawhara). Households were then sampled from each
selected district and all the individuals aged 40 years or over living in the selected households
were invited to participate in the study.
Outcome measurements
Spirometry was performed according to the American Thoracic Society (ATS) criteria by
trained and BOLD-certified technicians who performed spirometry on participants before and
15 minutes after administering 200 μg of salbutamol (Ventolin; GlaxoSmithKline,Middlesex,
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UK) via metered-dose inhaler with a one-way valve volumatic spacer (Volumatic; GlaxoSmith-
Kline; Research Triangle Park, NC) [13]. Portable spirometers (EasyOnendd.Medizintechnik;
Zurich, Switzerland) were used in this study and were checked for calibration daily, using a
3.00-liter syringe. All spirometry data were reviewed and graded for quality by the BOLD Pul-
monary Function Quality Control Center. The quality of spirometry maneuvers was monitored
regularly, and technicians whose quality scores dropped below pre-specified levels were
retrained. Acceptability and reproducibility were assessed according to the ATS/ERS 2005 cri-
teria as described by Enright and colleagues [14]. Only tests that met high quality scores were
used for the final analysis.
Questionnaires data
The questionnaires data were obtained by trained and certified interviewers who conducted
face-to-face interviews in the participant’s native language. The questionnaires used in this
study assessed data on the medical history and disease symptoms, risk behaviors for COPD,
co-morbidities, respiratory diagnoses and activity limitation [12].
Definitions
According to the Global Initiative of Lung Disease (GOLD) guidelines, COPD was defined as a
post-BD FEV1/FVC< 0.7 [15]. COPD stages were categorized as: Stage I: if FEV1 80% pre-
dicted; Stage II: if FEV1 50 and< 80% predicted; Stage III: if FEV1 30 and< 50% pre-
dicted; and Stage IV: if FEV1< 30% predicted [15–16]. The third US National Health and
Nutrition Examination Survey (NHANES III) was used for computing predicted values and
lower limits of normal (LLNs) [17].
Nonsmokers referred to subjects who had smoked on average<1 cigarette/day for<1 year
or had never smoked, ex-smokers were subjects who had ceased smoking at least 12 months
prior to the interview and ever smokers (current or former smokers) were defined as persons
who had smoked> 20 packs of cigarettes in a lifetime or> 1 cigarette/day for a year. Non-
smokers exposed to COPD risk factors were grouped and their data analyzed to determine the
specific characteristics of COPD in these subjects in comparison to smokers with COPD.
The following information were also collected: Body mass index (BMI) value (Kg/m2), num-
ber of years of education, hospitalization for breathing problems prior to the age of 10 years,
respiratory symptoms (cough, phlegm, wheezing, and dyspnoea), physician diagnosis of
asthma, emphysema, COPD or tuberculosis and comorbidity (heart disease, hypertension,
diabetes).
Family history of obstructive airway disease was defined as an affirmative answer to whether
the participant reported a first-degree relative with asthma, chronic bronchitis, emphysema or
COPD.
The use of bronchodilating treatment was considered positive if the subject affirmed past or
current use of any medication for the treatment of bronchoconstriction.
Exposure to environmental tobacco smoke during childhood was considered positive if a
household member smoked cigarettes in the home during the subject’s childhood.
Current exposure to cigarette smoke was reported separately for the home and the work
place. Exposure at home was present if a person in the household had smoked cigarette, pipe,
or cigar during the past two weeks. Exposure at work was present if the participant smelled
tobacco smoke at the workplace for more than 4h/day.
To assess long-term occupational exposure to airway irritants, participants were asked
whether they had worked3 months in one of the following three categories of occupations:
(1) organic dust (farming; flour-, feed-, or grain-milling; cotton- or jute-processing; forestry-
COPD in Nonsmokers
PLOS ONE | DOI:10.1371/journal.pone.0151981 March 24, 2016 3 / 17
or wood-milling; and fish-processing); (2) inorganic dust (asbestos, aluminum, coal, or hard-
rock mining; tunneling, foundry, or steel-milling; and sandblasting); (3) irritant gazes, fumes
or vapors (through welding, fire fighting, chemical or plastic manufacturing, public transporta-
tion, and dry-cleaning chemicals).
Measures of biomass exposure were based on self-reported responses indicating if partici-
pants had experienced at least 6 months’ exposure to indoor open fire using coal, coke, wood,
crop residue or dung.
Statistical analysis
BOLD participants who completed the study questionnaires and had acceptable postbroncho-
dilator spirometry measures were included in the present analysis. Bivariate comparisons were
performed using Student T test to compare continuous measures across groups and χ2 tests to
compare categorical measures.
Calculations of odd ratios (ORs) and 95% CI values for COPD in relation to potential risk
factors were performed with multivariate logistic regression models. Models included gender;
age category (40–49, 50–59, 60–69 and 70+ years); years of school; occupational exposure to
gases, vapors or fumes; and indicators for10years of exposure to cooking biomass and heat-
ing biomass; passive-smoking exposure; hospitalization for breathing problems during child-
hood; self-reported physician-diagnosed conditions including asthma, cardiovascular disease,
hypertension or diabetes and BMI category (<20, 20–25, 25–30, 30–35 and35). All statistical
tests were performed with IBM SPSS statistics software (version 20), and a P value of<0.05
was considered statistically significant.
Results
Sample description
Of the 807 subjects sampled from Sousse region in Tunisia, 717 responders were included in
the final analysis. Responders were randomly included to the study and the response rate was
90%. 77 non-responders and 13 ineligible participants were excluded from the study for the fol-
lowing reasons: refusals, contact failures, spirometry ineligibility, and failed attempts. Among
the 717 interviewees, 56 failed to complete the spirometry testing and 661 completed accept-
able and reproducible post-BD spirometry and questionnaires. There were no significant dif-
ferences in age, sex and smoking status between responders and non-responders, suggesting
that the study participants are highly representative of the general population “Table 1”.
Among all participating subjects, nonsmokers accounted for 73.4% (n = 485), of whom
32.8% were males and 67.2% were females. Nonsmokers were more likely to be women in all
age groups while current smokers were predominately males. Study subjects with more than 20
pack-years of smoking history added up to 24.4%. Characteristics of the study population are
summarized in Table 2.
Respiratory symptoms in nonsmokers
Prevalence of non-reversible airway obstruction in nonsmokers. In nonsmokers, the
prevalence of non-reversible airway obstruction (GOLD grade I or higher COPD) was 4.7%
compared to 15.9% among current smokers (X2 = 22.61, p<0.01). 3.7% of nonsmokers and
4.1% of smokers met the criteria for GOLD grade II COPD (Fig 1). Of all the subjects fulfilling
the GOLD spirometric criteria of airway obstruction, nonsmokers accounted for 45.1%: 38.4%
of all GOLD grade I cases and 47.4% of all GOLD grade II cases. Overall, the prevalence of
GOLD grade I+ COPD was 7.8% (1.2) and of GOLD grade II COPD was 5.7% (1.1).
COPD in Nonsmokers
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When the LLN was used as a threshold for the FEV1/FVC ratio instead of the fixed ratio of
0.7, prevalence of airway obstruction among nonsmokers (FEV1/FVC< LLN and FEV1< 80%
predicted) was similar to that found using the GOLD fixed ratio (3.1% (1.2) vs 3.5% (1.5)
respectively).
The prevalence of GOLD grade I+ COPD increased with age in both sexes but was statisti-
cally significant only in the male group (p<0.01). For each age group, the prevalence of GOLD
grade I+ COPD was greater in men than in women (X2 = 57.85, p<0.01) (Fig 2).
Among smokers, COPD prevalence was generally higher in men than in women (8.41% ver-
sus 0.5%, X2 = 35.76, p<0.01). The same trend was noticed for nonsmokers and the prevalence
of both GOLD grade I and grade II COPD was significantly higher in males than in females
(1.3% versus 0.3% and 4.5% versus 1.1% respectively; X2 = 22.73, p<0.05) (Figs 3 and 4). Non-
smokers with GOLD grade II COPD had approximately the same age than smokers.
In smokers, as expected, prevalence of COPD (GOLD grade I and II) increased with increas-
ing pack-years of cigarette smoking in both men and women. The prevalence of airflow
Table 1. Comparison of responders and non-responders.
Responders N (%) Non responders N (%) P-value* X2-value
Gender 0.752 15.47
Male 331 (46.16) 37 (48.05)
Female 386 (53.83) 40 (51.94)
Age group, yr 0.805 7.23
40–49 263 (36.68) 25 (32.47)
50–59 290 (40.44) 33 (42.86)
60–69 118 (16.45) 15 (19.48)
70+ 46 (6.41) 4(5.19)
Smoking status 0.597 25.86
Current smoker 196 (27.33) 20 (25.97)
Nonsmoker 521 (72.66) 57 (74.02)
Total 717 (90.99) 77 (9.01)
* Two-sided p-value based on Pearson chi-square test.
Responders are subjects that answered the core questionnaire and performed post BD spirometry regardless of quality.
doi:10.1371/journal.pone.0151981.t001
Table 2. Population characteristics for smokers and nonsmokers.
Men (n = 309) Women (n = 352)
Characteristics Nonsmokers Smokers Nonsmokers Smokers
Subjects, No. (%) 159 (24) 150 (22.7) 326 (49.3) 26 (4)
Age, mean (SD), y 55 (9) 51 (9) 52 (8) 50 (8)
Age category, No. (%)
40–49 28 (9.1) 88 (28.5) 117 (33.2) 16(4.5)
50–59 28 (9.1) 90 (29.1) 140 (39.8) 13 (3.7)
60–69 18(5.8) 39(12.6) 46 (13.1) 2 (0.6)
70 4 (1.3) 14(4.5) 17 (4.8) 1 (0.3)
BMI, mean (SD) kg/m2 29.14 (12.06) 25.54 (4.61) 31.45 (5.64) 28.89 (5.42)
Education, mean (SD), y 3.43 (1.46) 3.40 (1.43) 2.45 (1.31) 2.92 (1.09)
Smoking,>20 pack-years, No. (%) - 36 (11.7) - 7 (2)
Data are presented as % unless otherwise indicated. Abbreviations: BMI, Body mass index
doi:10.1371/journal.pone.0151981.t002
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obstruction in subjects with GOLD grade I COPD increased from 3.5% in non smoking sub-
jects to 16.1% in those with a smoking history 20 pack-years. Similarly, the prevalence of
GOLD grade II COPD increased from 2.7% in non-smoking subjects to 8.2% in those with the
most pack-years of smoking.
Clinical profile of COPD in nonsmokers. Males accounted for the majority of non-smok-
ing COPD subjects. Among subjects with GOLD grade I+ COPD, there was no significant differ-
ence between smokers and nonsmokers in age, BMI, education, FEV1/FVC ratio, FEV1%
predicted values, family history of obstructive airway diseases, physician diagnosis of emphysema,
history of exposition to passive smoking during childhood, exposition to biomass smoke for heat-
ing and percentage and duration of occupational exposure to dusts/gases/fumes “Table 3”.
Fig 1. Prevalence (%) of COPD in smokers and nonsmokers respectively by disease severity.COPD:
Chronic Obstructive Pulmonary Disease; GOLD I: Global Initiative for Chronic Obstructive Lung Disease
Stage I COPD; *: p<0.01, Significant difference between smokers and nonsmokers.
doi:10.1371/journal.pone.0151981.g001
Fig 2. Prevalence of COPD (GOLD I and higher COPD) by gender and age groups.Chronic Obstructive
Pulmonary Disease; GOLD I: Global Initiative for Chronic Obstructive Lung Disease Stage I COPD; *:
p<0.01, Significant difference between male and female according to age.
doi:10.1371/journal.pone.0151981.g002
COPD in Nonsmokers
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Unlike those with smoking related COPD, nonsmoking COPD patients were less likely to
have chronic sputum production, cough, wheezing, dyspnoea and to use medications for respi-
ratory disease (X2 = 17.10, p<0.05) while more likely to have received a physician diagnosis of
asthma and to have suffered from respiratory diseases during their childhood (X2 = 82.84
p<0.01). Nonsmoking GOLD grade I+ COPD patients also reported a significantly higher rate
Fig 3. Population characteristics of male smokers and nonsmokers. COPD: Chronic Obstructive
Pulmonary Disease; GOLD I: Global Initiative for Chronic Obstructive Lung Disease Grade I COPD; GOLD II:
Global Initiative for Chronic Obstructive Lung Disease Grade II COPD.
doi:10.1371/journal.pone.0151981.g003
Fig 4. Population characteristics of female smokers and nonsmokers. COPD: Chronic Obstructive
Pulmonary Disease; GOLD I: Global Initiative for Chronic Obstructive Lung Disease Grade I COPD; GOLD II:
Global Initiative for Chronic Obstructive Lung Disease Grade II COPD.
doi:10.1371/journal.pone.0151981.g004
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of co-morbidities than smokers with COPD and than healthy nonsmokers (X2 = 7.65, p<0.05)
“Table 3”.
Surprisingly, nonsmoking women with airway obstruction produced significantly more spu-
tum and suffered more frequently from chronic cough than smoking women (13.9% vs 0% and
12% vs 0%, respectively) (X2 = 7.23, p<0.05). This difference could be explained by the healthy
smoker effect since smokers that don’t quit most often are those without symptoms.
When comparing nonsmokers with versus without airflow obstruction significantly more
symptoms and higher co-morbidity were found in the first group “Table 4”. Indeed, chronic
sputum production, wheezing, dyspnoea, current use of medication for obstructive airway dis-
ease and respiratory care utilization tended to be significantly more frequent in nonsmokers
with GOLD grade I+ COPD compared to those without. In addition, a prior diagnosis of
Table 3. Characteristics of chronic obstructive pulmonary disease (COPD) among nonsmokers compared with those in smokers.
Smoking COPD Non-smoking COPD P-value
Characteristics
Subjects, No. (%) 28 (55) 23 (45)
Age, mean (SD), y 61.39 (9.04) 62.74 (11.23) 0.252
Sex, female 7.1% 21.7% <0.01
BMI, mean (SD), Kg/m2 24.16 (5.01) 29.27 (4.98) 0.801
Education, mean (SD), y 8.43 (4.88) 8.61 (4.78) 0.892
FEV1% pred, mean (SD) 50.10 (15.65) 46.46 (13.89) 0.295
FEV1/FVC %, mean (SD) 61.31 (9.37) 61.14 (9.07) 0.981
Hospitalized for breathing problems<age of 10 0% 4.34% 0.02
Family history of obstructive airway diseases 3.57% 4.34% 0.755
Doctor-Diagnosed COPD 7.1% 0% <0.01
Use of medication for respiratory disease 21.4% 17.4% <0.01
Previous contact with health care due to respiratory symptoms 32.1% 39.1% <0.01
Respiratory symptoms
Chronic sputum production 57.1% 39.1% 0.01
Chronic cough 50% 21.7% 0.03
Wheezing 50% 47.8% <0.01
Dyspnoea 53.2% 50% 0.01
Reported co-morbidities
Asthma 14.3% 30.4% <0.01
Heart disease 0% 17.4% 0.021
Hypertension 21.4% 43.5% 0.025
Diabetes 7.1% 17.4% 0.494
Chronic bronchitis 10.7% 13% <0.01
Emphysema 3.6% 4.3% 0.332
TB 0% 0% -
Reported exposures
Passive smoking at home 14.3% 21.7% 0.011
Exposition to passive smoking during childhood 64.3% 52.2% 0.631
Indoor open ﬁre with biomass for cooking 21.4% 39.1% 0.007
Indoor open ﬁre with biomass for heating 53.6% 65.2% 0.283
Gases/fumes/vapors in the workplace 64.3% 65.2% 0.554
Data are presented as % unless otherwise indicated. Abbreviations: BMI, Body mass index; FEV1: Forced expiratory volume in one second; FVC: Forced
vital capacity, %pred: percentage predicted.
doi:10.1371/journal.pone.0151981.t003
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asthma, heart disease, hypertension and chronic bronchitis but not emphysema, was signifi-
cantly more common among nonsmokers with GOLD grade I+ COPD compared to nonsmok-
ers with normal lung function “Table 4”. Current or prior use of medication for obstructive
airway disease was significantly more common among nonsmokers with COPD compared to
those without airflow obstruction but also significantly lower compared to smoking COPD
patients. Of nonsmokers with GOLD garde I+ COPD, 30.4% had received a prior diagnosis of
asthma and 13% had a prior diagnosis of chronic bronchitis and these results were significantly
different from those of the healthy nonsmokers (X2 = 27.04, p<0.01). However, among smok-
ers with the same disease, only 14.3% had received a prior diagnosis of asthma and 10.7% a
prior diagnosis of chronic bronchitis “Table 4”. Moreover, nonsmoking patients with a grade II
COPD received significantly more physician diagnosis of asthma than those with a grade I
COPD (X2 = 12.2, p<0.01).
Table 4. Respiratory symptoms, co-morbidity, family history of obstructive airway disease, health care consumption and previous physician diag-
nosis of airway disease in nonsmokers with and without non-reversible airway obstruction.
FEV1/FVC<0.7 FEV1/FVC>0.7 P-value
Characteristics
Age, mean (SD) 62.74 (11.23) 53.22 (8.64) 0.075
Sex, female 21.7% 69.5% <0.01
FEV1/FVC (%) 61.14 (9.07) 79.74 (5.17) <0.01
BMI (Kg/m2) 29.27 (4.98) 30.76 (8.5) 0.715
FEV1 (% pred) 46.46 (13.89) 70.30 (12.99) 0.845
Education12 years 30.4% 26.6% 0.687
Hospitalized for breathing problems<age of 10 4.3% 2.8% 0.750
Doctor-Diagnosed COPD 0% 0.4% 0.752
Family history of obstructive airway diseases 4.3% 6.7% 0.656
Use of medication for respiratory disease 17.4% 4.8% <0.01
Previous contact with health care due to respiratory symptoms 39.1% 10% <0.01
Respiratory symptoms
Chronic sputum production 39.1% 23.4% 0.085
Chronic cough 21.7% 24.9% 0.732
Wheezing 47.8% 20.8 <0.01
Dyspnoea 50% 10.6% 0.019
Reported co-morbidities
Asthma 30.4% 8.9% <0.01
Heart disease 17.4% 5.6% 0.022
Hypertension 43.5% 23.2% 0.026
Diabetes 17.4% 11.7% 0.411
Chronic bronchitis 13% 2.4% <0.01
Emphysema 4.3% 1.3% 0.231
TB 0% 0% -
Reported exposures
Passive smoking 21.7% 40.7% 0.07
Indoor open ﬁre with biomass for cooking 39.1% 17.3% <0.01
Indoor open ﬁre with biomass for heating 65.2% 50.2% 0.247
Irritant gases/fumes/vapors in the workplace 65.2% 51.3 0.192
Data are presented as % unless otherwise indicated. Abbreviations: BMI, Body mass index; FEV1: Forced expiratory volume in one second; FVC: Forced
vital capacity, %pred: percentage predicted.
doi:10.1371/journal.pone.0151981.t004
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Reported doctor-diagnosed chronic airway disease
In both smokers and nonsmokers with COPD, the prevalence of reported doctor-diagnosed
chronic bronchitis, emphysema or COPD was far lower than that determined by spirometry.
Indeed, none of the nonsmokers with COPD had ever received a previous doctor diagnosis of
chronic bronchitis, emphysema or COPD compared to 7.1% of smokers (X2 = 20.81, p<0.01).
In addition, only 39.1% of the nonsmokers and 32.1% of smokers with airflow obstruction had
ever been tested by lung function tests (spirometry) (X2 = 28.52, p<0.01). The self-reported
doctor-diagnosed COPD prevalence was higher in the smoking females than males and no
clear trend was seen between the prevalence of doctor-diagnosed chronic bronchitis, asthma,
emphysema or COPD and the smoking subjects’ age.
Risk factors for COPD among nonsmokers
We performed univariate and multivariate logistic regression to assess the association of
COPD with gender, age, education, exposure to occupational dusts/gases/fumes, to biomass
smokes and to passive smoking, childhood history of respiratory disease, comorbidities diagno-
sis and BMI “Table 5”. After mutual adjustment for all these potential factors in the model, we
Table 5. Independent predictors of GOLD stage I+ COPD in nonsmokers: Multivariate logistic model.
Variable OR 95% CI P Value
Gender
Male 14.837 2.626–83.836 0.002
Female Reference - -
Age category, y
40–49 Reference - -
50–59 3.046 0.500–18.549 0.227
60–69 3.612 0.514–25.362 0.197
70 57.769 6.317–528.327 <0.01
Education, y
1-y increase 1.996 0.396–10.054 0.402
High-risk occupation, y
10-y exposure 0.781 0.116–5.240 0.799
10-y exposure 1.87 1.140–12.863 0.015
Biomass fuel
 10-y cooking 1.479 0.373–5.855 0.578
 10-y heating 0.760 0.198–2.921 0.690
Passive smoking
Exposed 0.546 0.193–1.545 0. 254
Childhood hospitalisation
Yes 3.075 0.350–27.017 0.311
Comorbidities, diagnosis
HD/HT/DM 1.758 0.585–5.282 0.315
Asthma 10.621 2.897–38.937 <0.01
BMI, Kg/m2
BMI<20 4.010 1.31–12.19 0.018
20BMI<25 Reference - -
25BMI<30 0.134 0.009–1.937 0.140
30BMI<35 0.165 0.011–2.466 0.192
BMI35 0.107 0.006–2.075 0.140
Abbreviations: DM = diabetes mellitus; HD = Heart disease; HT = hypertension; BMI, Body mass index.
doi:10.1371/journal.pone.0151981.t005
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found that in our study population, the most predominant risk factor for airway obstruction
among nonsmokers was increasing age. Indeed, COPD was significantly more common in sub-
jects aged 70+ years (OR = 21.61, p = 0.001) compared to subjects aged 40–49 years. Male gen-
der and occupational exposure to dusts/gases/fumes were also associated with an increased
likelihood of developing stage I+ COPD, whereas biomass smokes exposure for cooking and
heating and less education were not associated with a risk of developing this disease. Moreover,
a previous diagnosis of asthma and a BMI<20kg/m2 constitute independent risk factors for
stage I+ COPD. However, in our data, education, area of domicile, socio-economic status and
family history of obstructive airway disease were not found to constitute significant risk factors
for non-reversible airway obstruction.
Discussion
The present study is the first to provide population-based estimates of the prevalence of airflow
obstruction in nonsmokers in Tunisia as defined by LLN, FEV1/FVC ratio and FEV1<0.70
predicted.
There were three main findings in this study: 1) our data confirm previous evidence that a
substantial proportion of individuals with COPD are nonsmokers and that they are usually
under diagnosed with the disease. 2) More than two-thirds of nonsmokers with mild to moder-
ate airway obstruction are men. 3) The most predominant risk factors for airway obstruction
among nonsmokers include advanced age, gender, occupational exposure, lower body mass
index and a previous diagnosis of asthma. This analysis of BOLD data in Tunisia also shows
that, nonsmokers accounted for almost the half (45%) of COPD cases. This proportion is
higher than described in other population based studies from developed countries like UK
(22.9%) and Spain (23.4%), but similar to the proportions reported among the COPD cases in
the United States (25%) and in China (38.6%) [18–19].
In our study population, 3.5% of the nonsmokers have at least stage I COPD. As with results
from other studies which used post-bronchodilation GOLD criteria to define and grade
COPD, prevalence of airflow obstruction in Tunisian nonsmokers appears in the lower range
both for males and females [20,21,22]. This finding remained valid when the fixed FEV1/FVC
ratio was used instead of the LLN. However, in comparison to other studies using the same
diagnostic criteria in the same age groups our results were similar to those found in Switzerland
(3.4%) [23], in China (4%) [24], in Germany (3.7%), in Canada (3.5%) and in Sweden (3.4%)
[22].
COPD does not develop suddenly, but rather exposure to risk factors over a considerable
period of time. Increasing age, in our population, is a strong risk factor for having COPD,
indeed, the prevalence of COPD increases with age in both smokers and nonsmokers and was
significantly higher in people70 years of age. These findings are consistent with the results of
other countries using the same BOLD methodology [22–24] and in many other previous epide-
miological studies who showed a steep gradient in COPD prevalence with increasing age in
both smokers and nonsmokers [10,20,25,26,27].Using a fixed FEV1/FVC ratio< 0.70 as a cut
point for airflow obstruction constitutes an important limitation and may lead to overestima-
tion of the disease prevalence in elderly nonsmokers since this ratio has a significant age-
related regression [28,29,30].
Nonetheless, using the LLN criterion in the evaluation of FEV1/FVC could be an alternative
to minimize the potential misclassification [31–32]. Indeed, several previous studies showed
that the use of the LLN criterion instead of the fixed ratio criterion minimizes known age biases
and better reflects clinically significant irreversible AO [28–30]. However, recent study has
demonstrated that individuals with FEV1/FVC ratio below 0.7 and above 5th percentile have
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indeed increased risk of COPD-related death or hospitalization [33]. The latter finding in part
justifies the using of a fixed FEV1/FVC ratio especially in epidemiological studies (such as
BOLD study), because this can help to identify subjects who may need medical attention.
The finding that increasing age is a risk factor for COPD in nonsmokers is in line with pre-
vious studies results [22,26,27]. However, the relationship with gender is not entirely clear,
indeed, some studies have found nonsmokers with airway obstruction to be predominately
male [23,5,24], while others have found female sex to be a risk factor for COPD [34,35,36].
In the present study, the prevalence of COPD among nonsmokers was higher in the oldest
old men than that seen in women and according to the multivariate analysis, male gender con-
stitutes a statistically significant risk factor of airway obstruction. This result is consistent with
findings from Germany, Norway, Philippines and Sweden [22–37] but in contrast with the
results from Austria, South Africa, Iceland, Poland and Australia which showed a greater prev-
alence of COPD among female in comparison to male nonsmokers [22,35,36].
There is actually a considerable controversy as to whether women are at greater risk than men
given an equal exposure to risk factors for COPD since they live longer than men and are more
likely to be exposed to high indoor air pollution levels especially in developing countries [34–38].
There is a lot of debate in the current literature whether exposure to biomass cooking may be a
risk factor for COPD, particularly in low income settings, however the evidence is contradictory
and more studies are needed to elucidate the relationship between gender and COPD [25–39].
In our study population, all of the nonsmokers and 92.9% of the smokers with GOLD grade
I+ COPD were previously undiagnosed. This huge gap between physician diagnosis of COPD
and the presence of airflow obstruction defined by spirometry, suggests that COPD diagnosis
based on symptoms may not be adequate. The lack of recognition and under-diagnosis of
obstructive lung disease among nonsmokers is possibly a result of little knowledge on this con-
dition and of a poor understanding and appreciation of risk factors other than smoking.
Our results also revealed that 30.4% of nonsmokers with significant non-reversible airway
obstruction reported a prior physician’s diagnosis of asthma compared to only 14.3% of smok-
ers (X2 = 16.47, p<0.01). In our material a previous diagnosis of asthma constitutes a statisti-
cally significant risk factor for COPD in nonsmokers. This result correlated well with the
literature indicated that asthma plays a specific and important role in increasing the risk of air-
flow obstruction in nonsmokers [25,40,41]. Indeed, a previous SAPALDIA publication
described this association extensively [40] and asthma has been recently found to be associated
with COPD in nonsmokers [23,8,41]. These findings are supported by recent genetic associa-
tion studies demonstrating that genetic nucleotide polymorphism variants appear to reduce
the risk of both asthma and COPD in smokers [41,42,43].
Nonetheless, in the present study, the fact that concomitant asthma and symptoms were
more prevalent in the nonsmoking group could theoretically explain the misdiagnosed COPD
cases in patients with asthma and chronic obstruction. Indeed, despite the availability of con-
sensus guideline diagnostic recommendations, diagnostic confusion between COPD and
asthma are common. Additional tests and tools can be helpful in the differential diagnosis,
including questionnaires specifically developed to discriminate between COPD and asthma
and, in special cases, imaging studies.
In our study, exposure to environmental tobacco smoke was not associated with COPD in
nonsmokers. Several researchers were also not able to identify passive smoking as a risk factor
for COPD [23,4,44]. However the latter contrasts with a recent Chinese study which found an
association between passive smoking exposure and airways obstruction in nonsmokers [24].
These conflicting results might be associated with the size of our study population.
In addition to well-documented causative factors for COPD in nonsmokers (such as age
and gender), other factors may also have a role in the aetiology of the disease [4]. Of these
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factors, low BMI has attracted general attention. Indeed, COPD can be associated with a pro-
gressive loss of skeletal muscle mass and according to several studies, low BMI is an indepen-
dent predictor of the risk of death [45–46]. Our data showed increased odds of COPD in
nonsmokers with low BMI (<20 kg/m2). Moreover, in the non-smoking group, the association
between BMI alterations and the presence of GOLD grade I+ COPD was more pronounced in
men than women. The same results were reported by Lamprecht et al in 2011 showing
increased odds of COPD in nonsmokers with a BMI<20kg/m2 [22]. Celli et al also found an
increased likelihood of obstruction in nonsmokers with low BMI [45]. Given the cross-sec-
tional nature of our data, we can-not discriminate whether low BMI precedes COPD or is
rather a consequence of the disease.
The current authors also found a small, but statistically significant, association between
COPD and occupational exposure to dusts, gases and fumes. Consistent associations have been
previously observed between exposure to workplace agents and COPD in multiple high-quality
epidemiological studies and an exposure-response gradient was demonstrated in several
researches [5–46]. Biological plausibility is supported by data from experimental studies dem-
onstrating the induction of chronic bronchitis and/or emphysema in animals after exposure to
several agents associated with COPD in epidemiological studies eg, endotoxin, mineral dusts,
sulfur dioxide and vanadium) have been shown to be capable of inducing pathologically
defined chronic bronchitis in animal models [22,47,48,49]. Thus, it is interesting to note that in
our study population, subjects who were exposed to occupational dusts, gases and fumes had
significantly more respiratory symptoms than others; indeed, our results showed that 92% of
nonsmokers exposed to occupational pollutants suffered frequently from chronic bronchitis.
Several agents known to be associated with clinically defined chronic bronchitis in humans has
been also shown to increase risk of chronic cough, lower FEV1, and lower FEV1/FVC indepen-
dent of personal tobacco use of these cohorts.
Another type of indoor pollution arises from coal and biomass combustion. In the present
study, 27% and 17% of nonsmokers have been exposed to biomass smoke and coal, respectively
and 88% had poor ventilation in the kitchen; among nonsmokers with COPD, 39% were
exposed to coal smoke and 84% had poor ventilation in the kitchen. Unlike in developed coun-
tries, indoor air pollution, including coal and biomass combustion, may contribute substan-
tially to COPD especially for subjects without smoking habits [24,50,51,52]. However, in the
present study, the correlation between levels of exposition and the prevalence of COPD didn’t
reach the statistical significance level.
In the present study, nonsmokers with GOLD grade I+ COPD reported significantly higher
amounts of co-morbidities (asthma, heart disease, hypertension and chronic bronchitis) than
both smoking COPD and healthy nonsmokers. This again supports the arguments of several
studies demonstrating that chronic airway obstruction in nonsmokers follows a similar course
and involves co-morbid disease in either instance [53].
Airflow obstruction in nonsmokers is important for several reasons: 1) compared with
smokers with airflow obstruction, symptoms are equally present, use of medication for respira-
tory disease is lower and respiratory care utilization tends to be higher. 2) Several diseases asso-
ciated with COPD in smokers are also reported in nonsmokers with COPD. For example,
Echave et al reported an association between low FEV1 and incidence of cardiovascular disease,
independently of smoking [53]. Other studies found an increased risk of lung cancer for non-
smokers with COPD compared to those without COPD [54–55].
Strengths of this study include the total number of subjects included, exact spirometry and
accurate mapping of risk factors. However, some limitations of the present research need to be
acknowledged: reference equations for spirometric variables are not available for North Africa;
BOLD uses the widely accepted prediction equations derived from the third US NHANES
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which may not ideally fit for all studied populations [56]. The use of a fixed threshold to define
airways obstruction is associated with some extent of misclassification [57]. When we used the
LLN instead of the fixed ratio, the proportion of nonsmokers among all cases of COPD
remains, however, almost unchanged.
Moreover, some analysis were limited because of the low number of nonsmokers with
COPD which limit our ability to draw conclusions regarding potential risk factors and because
of the design of the questionnaires which were intended to be comprehensive and easy to
administer but were based on self-reporting, and the latter can be subject to inaccurate recall.
Conclusions
In this study, the prevalence, profiles and potential risk factors for GOLD grade I and higher
COPD were elucidated among nonsmokers. The results revealed that nonsmokers constitute a
substantial proportion of COPD patients, indeed, 45% of the participants with obstruction are
nonsmokers, this prevalence appear to be at the higher range compared to other parts of the
world with similar age distribution. Multiple risk factors, other than tobacco smoke, play a key
role in the development and pathogenesis of COPD among nonsmokers as increasing age,
male gender, lower BMI, exposure to occupational irritants and a prior diagnosis of asthma.
The nonsmokers with airway obstruction had also significantly more symptoms and more co-
morbid condition than both smoking COPD and healthy nonsmokers. Therefore, compared
with the condition in smokers, airflow obstruction in non- smokers may arise from a different
aetiology.
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